{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:31:20Z","timestamp":1791412280894,"version":"4.3.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-03827-6","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T15:46:08Z","timestamp":1738943168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of rituximab on IgG and IgM levels in patients with autoimmune bullous diseases: a cohort study"],"prefix":"10.1007","volume":"317","author":[{"given":"Zeinab","family":"Dalvand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-1432","authenticated-orcid":false,"given":"Ahmad","family":"Vafaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Balighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-1005","authenticated-orcid":false,"given":"Hamidreza","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Dasdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Kianfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Shalviri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-8895","authenticated-orcid":false,"given":"Maryam","family":"Daneshpazhooh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"3827_CR1","doi-asserted-by":"crossref","unstructured":"Olasz EB, Yancey KB Bullous Pemphigoid and Related Subepidermal Autoimmune Blistering Diseases. Dermatologic Immunity. Current Directions in Autoimmunity2008. pp. 141\u2013\u200966","DOI":"10.1159\/000131452"},{"key":"3827_CR2","doi-asserted-by":"crossref","unstructured":"Olbrich M, K\u00fcnstner A, Witte M, Busch H, F\u00e4hnrich A (2019) Genetics and Omics Analysis of Autoimmune skin blistering diseases. Front Immunol.;10","DOI":"10.3389\/fimmu.2019.02327"},{"issue":"2","key":"3827_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.det.2018.12.003","volume":"37","author":"K Kridin","year":"2019","unstructured":"Kridin K, Ahn C, Huang WC, Ansari A, Sami N (2019) Treatment update of Autoimmune Blistering diseases. Dermatol Clin 37(2):215\u2013228","journal-title":"Dermatol Clin"},{"issue":"10083","key":"3827_CR4","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S et al (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389(10083):2031\u20132040","journal-title":"Lancet"},{"issue":"9","key":"3827_CR5","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.16752","volume":"34","author":"P Joly","year":"2020","unstructured":"Joly P, Horvath B, Patsatsi A, Uzun S, Bech R, Beissert S et al (2020) Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 34(9):1900\u20131913","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"175","key":"3827_CR6","doi-asserted-by":"publisher","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","volume":"5","author":"N Colliou","year":"2013","unstructured":"Colliou N, Picard D, Caillot F, Calbo S, Le Corre S, Lim A et al (2013) Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med 5(175):175ra30","journal-title":"Sci Transl Med"},{"issue":"3","key":"3827_CR7","doi-asserted-by":"publisher","first-page":"102466","DOI":"10.1016\/j.autrev.2020.102466","volume":"19","author":"K Kridin","year":"2020","unstructured":"Kridin K, Ahmed AR (2020) Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun Rev 19(3):102466","journal-title":"Autoimmun Rev"},{"issue":"5 Pt 1","key":"3827_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transpl 6(5 Pt 1):859\u2013866","journal-title":"Am J Transpl"},{"issue":"6","key":"3827_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","volume":"130","author":"TS Athni","year":"2023","unstructured":"Athni TS, Barmettler S (2023) Hypogammaglobulinemia, late-onset neutropenia, and infections following Rituximab. Ann Allergy Asthma Immunol 130(6):699\u2013712","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3827_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13555-012-0017-3","volume":"2","author":"LR Zakka","year":"2012","unstructured":"Zakka LR, Shetty SS, Ahmed AR (2012) Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb) 2(1):17","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"3827_CR11","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of Immunoglobulin Levels, infectious risk, and Mortality with Rituximab and Hypogammaglobulinemia. JAMA Netw Open 1(7):e184169","journal-title":"JAMA Netw Open"},{"issue":"6","key":"3827_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/acr.22993","volume":"69","author":"V Reddy","year":"2017","unstructured":"Reddy V, Martinez L, Isenberg DA, Leandro MJ, Cambridge G (2017) Pragmatic treatment of patients with systemic Lupus Erythematosus with Rituximab: Long-Term effects on serum immunoglobulins. Arthritis Care Res (Hoboken) 69(6):857\u2013866","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3827_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S et al (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60\u201365","journal-title":"J Autoimmun"},{"key":"3827_CR14","doi-asserted-by":"publisher","first-page":"727520","DOI":"10.3389\/fimmu.2021.727520","volume":"12","author":"AR Ahmed","year":"2021","unstructured":"Ahmed AR, Aksoy M (2021) IgM Deficiency in Autoimmune Blistering Mucocutaneous diseases following various treatments: Long Term Follow-Up and relevant observations. Front Immunol 12:727520","journal-title":"Front Immunol"},{"key":"3827_CR15","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE et al (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37(3):558\u2013567","DOI":"10.3899\/jrheum.090856"},{"issue":"10","key":"3827_CR16","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","volume":"53","author":"E Besada","year":"2014","unstructured":"Besada E, Koldingsnes W, Nossent JC (2014) Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 53(10):1818\u20131824","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3827_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","volume":"51","author":"I De La Torre","year":"2012","unstructured":"De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G (2012) Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford) 51(5):833\u2013840","journal-title":"Rheumatology (Oxford)"},{"key":"3827_CR18","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72(9):1496\u20131502","DOI":"10.1136\/annrheumdis-2012-201956"},{"issue":"3","key":"3827_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/BOR.0000000000000377","volume":"29","author":"R Kado","year":"2017","unstructured":"Kado R, Sanders G, McCune WJ (2017) Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy. Curr Opin Rheumatol 29(3):228\u2013233","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"3827_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jaci.2021.03.041","volume":"148","author":"R Labrosse","year":"2021","unstructured":"Labrosse R, Barmettler S, Derfalvi B, Blincoe A, Cros G, Lacombe-Barrios J et al (2021) Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. J Allergy Clin Immunol 148(2):523\u2013532 e8","journal-title":"J Allergy Clin Immunol"},{"key":"3827_CR21","doi-asserted-by":"publisher","first-page":"671503","DOI":"10.3389\/fimmu.2021.671503","volume":"12","author":"J Tieu","year":"2021","unstructured":"Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A et al (2021) Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease. Front Immunol 12:671503","journal-title":"Front Immunol"},{"issue":"12","key":"3827_CR22","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/jid.2008.178","volume":"128","author":"H Mouquet","year":"2008","unstructured":"Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemercier B, Lim A et al (2008) B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 128(12):2859\u20132869","journal-title":"J Invest Dermatol"},{"issue":"6","key":"3827_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","volume":"36","author":"EAA Christou","year":"2017","unstructured":"Christou EAA, Giardino G, Worth A, Ladomenou F (2017) Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab. Int Rev Immunol 36(6):352\u2013359","journal-title":"Int Rev Immunol"},{"issue":"4","key":"3827_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s10157-020-01858-z","volume":"24","author":"S Fujinaga","year":"2020","unstructured":"Fujinaga S, Tomii Y (2020) Profound effect of post-rituximab mycophenolate mofetil administration for persistent hypogammaglobulinemia in young children with steroid-dependent nephrotic syndrome. Clin Exp Nephrol 24(4):386\u2013387","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"3827_CR25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00296-021-04847-x","volume":"41","author":"SD Wade","year":"2021","unstructured":"Wade SD, Kyttaris VC (2021) Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study. Rheumatol Int 41(6):1115\u20131124","journal-title":"Rheumatol Int"},{"issue":"4","key":"3827_CR26","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/rheumatology\/keab626","volume":"61","author":"MS Ong","year":"2022","unstructured":"Ong MS, Rothman D, Barmettler S, Son MB, Lo M, Roberts J et al (2022) New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases. Rheumatology (Oxford) 61(4):1610\u20131620","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"3827_CR27","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.40937","volume":"71","author":"MY Md Yusof","year":"2019","unstructured":"Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S et al (2019) Predicting severe infection and effects of Hypogammaglobulinemia during Therapy with Rituximab in Rheumatic and Musculoskeletal diseases. Arthritis Rheumatol 71(11):1812\u20131823","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"3827_CR28","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J et al (2007) Safety and efficacy of additional courses of Rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56(12):3896\u20133908","journal-title":"Arthritis Rheum"},{"issue":"3","key":"3827_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221\u2013232","journal-title":"N Engl J Med"},{"issue":"5","key":"3827_CR30","doi-asserted-by":"publisher","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","volume":"7","author":"N Venhoff","year":"2012","unstructured":"Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D et al (2012) Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE 7(5):e37626","journal-title":"PLoS ONE"},{"issue":"1","key":"3827_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0609.2008.01165.x","volume":"82","author":"Y Kanbayashi","year":"2009","unstructured":"Kanbayashi Y, Nomura K, Fujimoto Y, Yamashita M, Ohshiro M, Okamoto K et al (2009) Risk factors for infection in haematology patients treated with rituximab. Eur J Haematol 82(1):26\u201330","journal-title":"Eur J Haematol"},{"key":"3827_CR32","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3389\/fimmu.2017.01056","volume":"8","author":"S Gupta","year":"2017","unstructured":"Gupta S, Gupta A (2017) Selective IgM Deficiency-An Underestimated Primary Immunodeficiency. Front Immunol 8:1056","journal-title":"Front Immunol"},{"issue":"6","key":"3827_CR33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T et al (2011) Updated consensus statement on the use of Rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(6):909\u2013920","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3827_CR34","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","volume":"53","author":"E Ntatsaki","year":"2014","unstructured":"Ntatsaki E, Carruthers D, Chakravarty K, D\u2019Cruz D, Harper L, Jayne D et al (2014) BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology 53(12):2306\u20132309","journal-title":"Rheumatology"},{"issue":"2","key":"3827_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","volume":"48","author":"G Boleto","year":"2018","unstructured":"Boleto G, Avouac J, Wipff J, Forien M, Dougados M, Roux C et al (2018) Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study. Semin Arthritis Rheum 48(2):149\u2013154","journal-title":"Semin Arthritis Rheum"},{"key":"3827_CR36","doi-asserted-by":"crossref","unstructured":"Fierro A, Andres M, Jdl T-A, Vela-Casasempere P, Mart\u00ednez-Vidal MP Ab0473\u2005hypogammaglobulinemia and infections in rheumatologic patients treated with Rituximab. Abstracts accepted for Publication2019. p. 17002\u201317001","DOI":"10.1136\/annrheumdis-2019-eular.3767"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-03827-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03827-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T15:46:14Z","timestamp":1738943174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-03827-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3827"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-03827-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients were informed about the study protocol, and written informed consent was obtained prior to participation. The study was conducted in accordance with the principles of the Declaration of Helsinki, and ethical approval was obtained from the Tehran University of Medical Sciences et committee for ethics with approval number of IR.TUMS.MEDICINE.REC.1399.898.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}